Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-DOTA-Daratumumab PET in Multiple Myeloma
NCT03311828Phase 1Completed
- Sponsor
- City of Hope
- Start
- Feb 2018
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 64Cu-DOTA-daratumumab in multiple myeloma (MM), sponsored by City of Hope. Primary endpoint: Incidence of adverse events at 7 days. Started Feb 2018; status: completed.
02
Drugs
64Cu-DOTA-daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03311828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03311828.